Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF)

Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and SAB Biotherapeutics (NASDAQ:SABS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Volatility and Risk

Quantum Genomics Société Anonyme has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Profitability

This table compares Quantum Genomics Société Anonyme and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Genomics Société Anonyme	N/A	N/A	N/A
SAB Biotherapeutics	-1,531.26%	-109.90%	-72.78%

Analyst Recommendations

This is a summary of recent ratings and price targets for Quantum Genomics Société Anonyme and SAB Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Genomics Société Anonyme	0	0	0	0	N/A
SAB Biotherapeutics	0	1	3	0	2.75

SAB Biotherapeutics has a consensus price target of $13.00, suggesting a potential upside of 345.21%. Given SAB Biotherapeutics’ higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Quantum Genomics Société Anonyme.

Valuation and Earnings

This table compares Quantum Genomics Société Anonyme and SAB Biotherapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A
SAB Biotherapeutics	$2.24 million	12.03	-$42.19 million	N/A	N/A

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than SAB Biotherapeutics.

Institutional and Insider Ownership

7.8% of SAB Biotherapeutics shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

SAB Biotherapeutics beats Quantum Genomics Société Anonyme on 6 of the 9 factors compared between the two stocks.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.